 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regional Court Dsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTechRuling on infringement to be provided latest once the validity...

CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany

This is a signal that CVAC's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

CureVac (CVAC, $8.01) RSI Indicator left the oversold zone on September 15, 2023

CureVac (CVAC, $8.12) RSI Indicator left the oversold zone on September 14, 2023

CureVac (CVAC, $8.12) RSI Indicator left the oversold zone on September 12, 2023

Phase 1 part of combined Phase 1/2 study assessed comprehensive series of flu vaccine candidates, featuring up to eight separate mRNA constructs per candidateBest-performing candidate providing broad...

CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage

The Delights Of The Pfizer/Moderna Catfight

 Authored by Robert Malone via The Brownstone Institute,

I am a bit embarrassed to admit that I am taking a perverse pleasure in watching this...

The Delights Of The Pfizer/Moderna Catfight

In trading on Tuesday, shares of CureVac NV (CVAC) crossed below their 200 day moving average of 8.67, changing hands as low as 8.62 per share. CureVac NV shares are currently trading off...

CureVac Breaks Below 200-Day Moving Average - Notable for CVAC

CureVac (NASDAQ:CVAC  Get Free Report) had its target price lowered by analysts at Bank of America from $10.00 to $8.00 in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage presently has an underperform rating on the stock. Bank of America...

CureVac (NASDAQ:CVAC) PT Lowered to $8.00

CureVac (NASDAQ:CVAC  Get Free Report) had its price objective reduced by research analysts at Bank of America from $10.00 to $8.00 in a research note issued to investors on Monday, MarketBeat.com reports. The firm presently has an underperform rating on the stock. Bank of ...

CureVac (NASDAQ:CVAC) Price Target Lowered to $8.00 at Bank of America

CureVac (NASDAQ:CVAC  Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $9.41, but opened at $9.08. CureVac shares last traded at $9.10, with a volume of 129,526 shares traded. Wall Street Analysts Forecast Growth CVAC has been the subject ...

CureVac (NASDAQ:CVAC) Shares Gap Down to $9.41

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Watchers	6,450
52-Wk Low	$5.63
52-Wk High	$12.79

Market Cap	$1.59B
Volume (M)	39,610.00
52-Wk High	$12.79
52-Wk Low	$5.63

CVAC CureVac N.V.

About

Feed

News

Sentiment

Earnings

Fundamentals